All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Sonali Smith is the Elwood V. Jensen Professor in Medicine and Interim Chief of the Section of Hematology/Oncology, as well as the Director of the Adult Lymphoma Program at the University of Chicago, Chicago, US. She was educated at the Northwestern University Feinberg School of Medicine, Chicago, US, and completed her residency at Northwestern Memorial Hospital, Chicago, US, before her fellowship at the University of Chicago. She is an expert in the care and treatment of adults with all types of Hodgkin and non-Hodgkin lymphomas, and her clinical research interest lies in the development of new agents and combinations in the management of both treatment-naïve and relapsed/refractory lymphomas.
She is the Principal Investigator on a number of clinical trials and, through her role as Vice-Chair of the Southwest Oncology Group (SWOG) Lymphoma Committee, she is involved in clinical trial development at the cooperative group level across the US. She serves on many national committees aiming to improve treatment options for lymphoma, and through her research has co-authored nearly 180 publications. Besides this, she is involved in education of peers and patients, giving frequent presentations and lectures.
Positions of responsibility/awards: